Umbilical cord monitoring of in utero drug exposure to buprenorphine and correlation with maternal dose and neonatal outcomes

Journal of Analytical Toxicology

Volumn 34, Issue 8, 2010, Pages 498-505

  Concheiro, Marta ^a,b   Jones, Hendreé E ^c   Johnson, Rolley E ^c,d   Choo, Robin ^e   Shakleya, Diaa M ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RECKITT BENCKISER   (United Kingdom)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; BUPRENORPHINE GLUCURONIDE; CANNABINOID; COCAINE; DIAMORPHINE; DRUG METABOLITE; GLUCURONIDE; METHADONE; MORPHINE; NORBUPRENORPHINE; NORBUPRENORPHINE GLUCURONIDE; OPIATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DEPENDENCE TREATMENT; DRUG DOSE REDUCTION; DRUG FECES LEVEL; DRUG MONITORING; DRUG TISSUE LEVEL; DRUG URINE LEVEL; FEMALE; HEROIN DEPENDENCE; HUMAN; HUMAN TISSUE; MALE; MECONIUM; NEWBORN; OUTCOME ASSESSMENT; PREDICTION; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RELAPSE; SENSITIVITY AND SPECIFICITY; THIRD TRIMESTER PREGNANCY; UMBILICAL CORD; URINALYSIS; WITHDRAWAL SYNDROME;

EID: 79954619260     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/34.8.498     Document Type: Article

References (28)

1. Drug Addiction Treatment Act of 2000. STAT. 1101, 2000, p 111.
2. C. Lejeune, L. Simmat-Durand, L. Gourarier, and S. Aubisson. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. Drug Alcohol Depend. 82: 250-257 (2006).
3. G. Fischer. Treatment of opioid dependence in pregnant women. Addiction 95: 1141-1144 (2000).
4. A. Dunlop, M. Panjari, H. O'Sullivan, P. Henschke, V. Love, A. Ritter, and N. Lintzeris. Clinical guidelines for the use of buprenorphine in pregnancy. Turning Point Alcohol and Drug Centre, Fitzroy, Australia, 2003.
5. H.E. Jones, P.R. Martin, S.H. Heil, K. Kaltenbach, P. Selby, M.G. Coyle, S.M. Stine, K.E. O'Grady, A.M. Arria, and G. Fischer. Treatment of opioid-dependent pregnant women: clinical and research issues. J. Subst. Abuse Treat. 35: 245-259 (2008).
6. C. Iribarne, D. Picart, Y. Dreano, J.P. Bail, and F. Berthou. Involvement of cytochrome P450 3A4 in n-dealkylation of buprenorphine in human liver microsomes. Life Sci. 60(22): 1953-1964 (1997).
7. C.D. King, M.D. Green, G.R. Rios, B.L. Coffman, I.S. Owens, W.P. Bishop, and T.R. Tephly. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch. Biochem. Biophys. 332: 92-100 (1996).
8. G. Rios and T. Tephly. Inhibition and active sites of UDP-glucuronosyltransferases 2B7 and 1A1. Drug Metab. Dispos. 30: 1364-1367 (2002).
9. K. Rouguieg, N. Picard, F.L. Sauvage, J.M. Gaulier, and P. Marquet. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab. Dispos. 38: 40-45 (2010).
10. J. Lozano, O. Garcia-Algar, O. Vall, R. de la Torre, G. Scaravelli, and S. Pichini. Biological matrices for the evaluation of in utero exposure to drugs of abuse. Ther. Drug Monit. 29: 711-734 (2007).
11. T. Gray and M. Huestis. Bioanalytical procedures for monitoring in utero drug exposure. Anal. Bioanal. Chem. 388: 1455-1465 (2007).
12. S. Pichini, I. Altieri, P. Zuccaro, and R. Pacifici. Drug monitoring in nonconventional biological fluids and matrices. Clin. Pharmacokinet. 30: 211-228 (1996).
13. S.L. Kacinko, H.E. Jones, R.E. Johnson, R.E. Choo, and M.A. Huestis. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin. Pharmacol. Ther. 84: 604-612 (2008).
14. H. Kilman. Umbilical cord. In Encyclopedia of Reproduction, Vol. 4, E. Knobil and J. Neil, Eds. Academic Press, San Diego, CA, 1999, pp 915-923.
15. D. Montgomery, C. Plate, S.C. Alder, M. Jones, J. Jones, and R.D. Christensen. Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium. J. Perinatol. 26: 11-14 (2006).
16. C.M. Moore, S. Brown, A. Negrusz, I. Tebbett, W. Meyer, and L. Jain. Determination of cocaine and its major metabolite, benzoylecgonine, in amniotic fluid, umbilical cord blood, umbilical cord tissue, and neonatal urine: a case study. J. Anal. Toxicol. 17: 62 (1993).
17. R.E.Winecker, B.A. Goldberger, I. Tebbett, M. Behnke, F.D. Eyler, M. Conlon, K.Wobie, J. Karlix, and R.L. Bertholf. Detection of cocaine and its metabolites in amniotic fluid and umbilical cord tissue. J. Anal. Toxicol. 21: 97-104 (1997).
18. H.E. Jones, R.E. Johnson, D.R. Jasinski, K.E. O'Grady, C.A. Chisholm, R.E. Choo, M. Crocetti, R. Dudas, C. Harrow, M.A. Huestis, L.M. Jansson, M. Lantz, B.M. Lester, and L. Milio. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 79: 1-10 (2005).
19. L.P. Finnegan and K. Kaltenbach. Neonatal abstinence syndrome. In Primary Pediatric Care, R.A. Hoekelman, S.B. Friedman, N.M. Nelson, and H.M. Seidel, Eds. Mosby Year Book, St. Louis, MO, 1992, pp 1367-1378.
20. M. Concheiro, D.M. Shakleya, and M.A. Huestis. Simultaneous quantification of buprenorphine, norbuprenorphine, buprenor-Huestis_jatoct10.qxd:JATLynneTemplate 9/8/10 9:28 AM Page 7phine-glucuronide and norbuprenorphine-glucuronide in human umbilical cord by liquid chromatography tandem mass spectrometry. Forensic Sci. Int. 188: 144-151 (2009).
21. A. de Castro, M. Concheiro, D. Shakleya, and M. Huestis. Development and validation of a liquid chromatography mass spectrometry assay for the simultaneous quantification of methadone, cocaine, opiates and metabolites in human umbilical cord. J. Chromatogr. B 877: 3065-3071 (2009).
22. M. Concheiro, H. Jones, R.E. Johnson, D.M. Shakleya, and M.A. Huestis. Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women. J. Chromatogr. B 878(1): 13-20 (2010).
23. F.M. Farin, T.H. Pohlman, and C.J. Omiecinski. Expression of cytochrome P450s and microsomal epoxide hydrolase in primary cultures of human umbilical vein endothelial cells. Toxicol. Appl. Pharmacol. 124: 1-9 (1994).
24. P. Marquet, P. Lavignasse, J. Gaulier, and G. Lachatre. Case study of neonates born to mothers undergoing buprenorphine maintenance treatment. In Buprenorphine Therapy of Opiate Addiction, P. Kintz and P. Marquet, Eds. Humana Press, Totowa, NJ, 2002, pp 125-135.
25. M. Garland, K.M. Abildskov, S. Taylor, K. Benzeroual, C.S. Caspersen, S.E. Arroyo, T.W. Kiu, B. Reznik, P. Weldy, S.S. Daniel, and R.I. Stark. Fetal morphine metabolism and clearance are constant during late gestation. Drug Metab. Dispos. 34: 636-646 (2006).
26. S.L. Kacinko, D.M. Shakleya, and M.A. Huestis. Validation and application of a method for the determination of buprenorphine, norbuprenorphine, and their glucuronide conjugates in human meconium. Anal. Chem. 80: 246-252 (2008).
27. T.R. Gray, D.M. Shakleya, amd M.A. Huestis. A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. Anal. Bioanal. Chem. 393: 1977-1990 (2009).
28. R. Boskovic, J. Klein, C. Woodland, C. Karaskov, and G. Koren. The role of the placenta in variability of fetal exposure to cocaine and cannabinoids: a twin study. Can. J. Physiol. Pharmacol. 79: 942-945 (2001).